Markets:

Overview

News

Currencies

International

Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

8.260 +0.410 (+5.22%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sionna Therapeutics, Inc. - Common Stock

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar ↗

September 08, 2025

Via Stocktwits

These stocks have an unusual volume in today's session ↗

August 13, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 12, 2026

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)...

Via Benzinga

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path ↗

August 11, 2026

Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue...

Via MarketBeat

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗

April 27, 2026

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story ↗

March 30, 2026

This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.

Via The Motley Fool

Topics Regulatory Compliance

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

Via The Motley Fool

Topics Regulatory Compliance

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗

March 15, 2026

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

Via The Motley Fool

Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares ↗

January 12, 2026

After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗

January 03, 2026

This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.

Via The Motley Fool

Topics Regulatory Compliance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 27, 2025

Via Benzinga

Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday ↗

July 02, 2025

Via Benzinga

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial ↗

June 04, 2025

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 22, 2025

Via Benzinga

Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

April 17, 2025

Via Benzinga

Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

April 17, 2025

Via Benzinga

AI Mobility Provider, Steel Veteran Made Trading Debuts ↗

March 02, 2025

AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology, and Singapore-based med-tech Basel Medical all made their public debuts...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

Sionna Therapeutics, Titan America Made Public Debut ↗

February 09, 2025

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial...

Via Talk Markets

Topics Stocks / Equities

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.